What development phase is Orabolin in?

Orabolin is FDA-approved (marketed).

What is the generic name of Orabolin?

ETHYLESTRENOL is the generic (nonproprietary) name of Orabolin.

Last reviewed 2026-04-20 · How we verify

Orabolin (ETHYLESTRENOL)

FDA-approved approved Small molecule Quality 15/100

Ethylestrenol (Orabolin) is a marketed drug that binds to the sodium-dependent serotonin transporter, though its primary indication and revenue figures are unspecified. A key strength of Ethylestrenol is its patent protection until 2028, providing a period of exclusivity before potential generic competition. The primary risk is the presence of multiple competitors targeting the same mechanism, including amfetamine, amiodarone, amitriptyline, amoxapine, and aripiprazole, with some already off-patent and available as generics.

At a glance

Generic name	ETHYLESTRENOL
Drug class	ethylestrenol
Target	Cytochrome P450 2C19, Acetylcholinesterase, Androgen receptor
Modality	Small molecule
Therapeutic area	Nephrology
Phase	FDA-approved
First approval	1964

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Orabolin CI brief — competitive landscape report
Orabolin updates RSS · CI watch RSS